InvestSMART

Anteris Technologies Ltd (ASX:AVR)

ALERT: Price-sensitive ASX Announcement for AVR
Current share price for AVR : $12.070 -0.48 (-3.82%)+
Announcement
Release
12 Aug 2026 8:31AM
Price at Release
$12.550
Full Release
download
Summary
Anteris Technologies Ltd reported their financial results for the second quarter of 2026, highlighting significant progress in the PARADIGM Trial, including securing U.S. Medicare reimbursement eligibility and initiating U.S. patient recruitment. The trial has been expanded to include Denmark and the Netherlands with regulatory approvals in Canada and France. Financially, the company reported net operating cash outflows of $20.8 million, mainly driven by R&D expenses of $23.4 million related to the scaling of manufacturing and clinical activities. The DurAVR® THV was showcased at a major symposium, underscoring its clinical developments.
Key Points
  • Anteris Technologies announced Q2 2026 financial results.
  • They secured U.S. Medicare reimbursement for the PARADIGM Trial.
  • Initiated U.S. recruitment for the PARADIGM Trial with the first patients enrolled in May 2026.
  • Expanded the PARADIGM Trial with recruitment in the U.S., Denmark, and the Netherlands.
  • Obtained regulatory clearance for the trial in Canada and France.
  • Financial results show net operating cash outflows of $20.8 million for Q2 2026.
  • R&D expenses reached $23.4 million due to manufacturing scale-up and trial-related activities.
  • The DurAVR® THV was highlighted at the New York Valves 2026 symposium.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.